[go: up one dir, main page]

MX2024006975A - Inhibidor de cdk9 y uso del mismo. - Google Patents

Inhibidor de cdk9 y uso del mismo.

Info

Publication number
MX2024006975A
MX2024006975A MX2024006975A MX2024006975A MX2024006975A MX 2024006975 A MX2024006975 A MX 2024006975A MX 2024006975 A MX2024006975 A MX 2024006975A MX 2024006975 A MX2024006975 A MX 2024006975A MX 2024006975 A MX2024006975 A MX 2024006975A
Authority
MX
Mexico
Prior art keywords
compounds
cdk9
cdk9 inhibitor
formula
relates
Prior art date
Application number
MX2024006975A
Other languages
English (en)
Inventor
Masanori Kawasaki
Frank Wu
Lin Li
Takuya Yokosaka
Wuwei Wang
Natsumi Miyano
Original Assignee
Transthera Sciences Nanjing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transthera Sciences Nanjing Inc filed Critical Transthera Sciences Nanjing Inc
Publication of MX2024006975A publication Critical patent/MX2024006975A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se engloba dentro del campo técnico de la medicina, y en particular se refiere a compuestos inhibidores de CDK9 tal como se muestra en la fórmula (I), su sal farmacéuticamente aceptable o isómero de los mismos, y también se refiere a composiciones farmacéuticas y una formulación farmacéutica de los compuestos y los usos de las mismas. X1, X2, R1, R2, R3, R6, A, L, n y m son como se definen en la descripción. Los compuestos se pueden usar para preparar fármacos para tratar o prevenir enfermedades relacionadas mediadas por CDK9. (ver Fórmula).
MX2024006975A 2021-12-16 2022-12-16 Inhibidor de cdk9 y uso del mismo. MX2024006975A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202111543257 2021-12-16
CN202210632338 2022-06-02
CN202210928526 2022-08-03
PCT/CN2022/139704 WO2023109959A1 (zh) 2021-12-16 2022-12-16 Cdk9抑制剂及其用途

Publications (1)

Publication Number Publication Date
MX2024006975A true MX2024006975A (es) 2024-08-27

Family

ID=86774913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006975A MX2024006975A (es) 2021-12-16 2022-12-16 Inhibidor de cdk9 y uso del mismo.

Country Status (12)

Country Link
US (1) US20250163043A1 (es)
EP (1) EP4450501A4 (es)
JP (1) JP2024545518A (es)
KR (1) KR20240130693A (es)
CN (1) CN116354957A (es)
AR (1) AR128015A1 (es)
AU (1) AU2022412837A1 (es)
CA (1) CA3240763A1 (es)
IL (1) IL313513A (es)
MX (1) MX2024006975A (es)
TW (1) TW202327592A (es)
WO (1) WO2023109959A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4558502A1 (en) * 2022-07-18 2025-05-28 Iambic Therapeutics, Inc. Aza-quinazoline compounds and methods of use
WO2024238574A1 (en) * 2023-05-15 2024-11-21 Aleksia Therapeutics, Inc. Cdk inhibitor compounds
WO2025155740A1 (en) * 2024-01-17 2025-07-24 Iambic Therapeutics, Inc. Combinations comprising aza-quinazoline compounds for use in the treatment of cancer
WO2025240517A1 (en) * 2024-05-14 2025-11-20 Aleksia Therapeutics, Inc. Cdk4 inhibitor naphthyridine compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100016291A (ko) * 2007-04-06 2010-02-12 노파르티스 아게 단백질 키나아제 억제제로 유용한 [2,6] 나프티리딘
CA2752265A1 (en) * 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
PT3305785T (pt) * 2015-05-29 2021-10-13 Teijin Pharma Ltd Derivado de pirido[3,4-d]pirimidina e seu sal farmaceuticamente aceitável
CN109996800B (zh) * 2016-11-28 2021-11-19 帝人制药株式会社 吡啶并[3,4-d]嘧啶衍生物或其溶剂合物的晶体
SI3546458T1 (sl) * 2016-11-28 2021-03-31 Teijin Pharma Limited Derivati ((piridin-2-il)-amino)pirido(3,4-d)pirimidina in ((piridazin-3-il)amino)pirido(3,4-d)pirimidina kot zaviralci CDK4/6 za zdravljenje npr. revmatoidnega artritisa, arterioskleroze, pljučne fibroze, možganske kapi ali raka
KR102889562B1 (ko) * 2019-09-26 2025-11-24 노파르티스 아게 아자-퀴놀린 화합물 및 그의 용도
WO2022037592A1 (zh) * 2020-08-17 2022-02-24 南京明德新药研发有限公司 嘧啶并环类化合物
CN116874503B (zh) * 2020-10-28 2025-08-08 杭州阿诺生物医药科技有限公司 一种高活性的hpk1激酶抑制剂

Also Published As

Publication number Publication date
TW202327592A (zh) 2023-07-16
AU2022412837A1 (en) 2024-06-13
CA3240763A1 (en) 2023-06-22
CN116354957A (zh) 2023-06-30
KR20240130693A (ko) 2024-08-29
WO2023109959A1 (zh) 2023-06-22
EP4450501A1 (en) 2024-10-23
AR128015A1 (es) 2024-03-20
EP4450501A4 (en) 2025-11-19
US20250163043A1 (en) 2025-05-22
IL313513A (en) 2024-08-01
JP2024545518A (ja) 2024-12-09

Similar Documents

Publication Publication Date Title
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
CL2020002695A1 (es) Péptidos macrocíclicos contra actinetobacter baumannii
AR132802A1 (es) 2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer
NZ763123A (en) Pde9 inhibitor and use thereof
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
AR098989A1 (es) Composiciones farmacéuticas que comprenden azd9291
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
UY40235A (es) Compuestos de heteroarilo para el tratamiento del dolor
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2021006724A (es) Compuestos de halo-alilamina y uso de los mismos.
DOP2022000076A (es) Inhibidores del factor d del complemento para administración oral
MX2023001725A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos.
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
MX2017009853A (es) Prevencion o tratamiento de enfermedades urinarias o gotosas.
MX2023011518A (es) Compuestos heterocíclicos novedosos y sus usos.
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")